TRIAL IN PROGRESS: PHASE I DOSE-ESCALATION STUDY OF VSV-GP (BI 1831169) MONOTHERAPY AND WITH EZABENLIMAB (BI 754091) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

被引：0

作者：

Porosnicu, Mercedes ^{[1
]}

Quinson, Anne-Marie ^{[2
]}

MacKay, Abi ^{[3
]}

Luecke, Stephan ^{[4
]}

Lauer, Ulrich M. ^{[5
]}

机构：

[1] Wake Forest Sch Med, Winston Salem, NC USA

[2] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[5] Univ Tubingen Hosp, Tubingen, Germany

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0628

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

628

引用

页码：A660 / A660

页数：1

共 50 条

[21] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors
Mross, K. B.
Scheulen, M. E.
Frost, A.
Scharr, D.
Richly, H.
Nokay, B.
Lee, K.
Hilbert, J.
Fleischer, F.
Fietz, O.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[22] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
Wu, Yi-Long
Cheng, Ying
Chen, Huajun
Tu, Haiyan
Xu, Chongrui
Wang, Zhen
Liu, Ying
Xin, Ying
Lou, Haizhou
Wang, Wei
Chin, Kevin
Li, Dandan
Zhao, Di
Gao, Yanfei
Xu, Wenping
Pan, Hongming
FUTURE ONCOLOGY, 2022,
[23] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Padda, Sukhmani K.
Krupitskaya, Yelena
Chhatwani, Laveena
Fisher, George A.
Colevas, Alexander D.
Pedro-Salcedo, Melanie San
Decker, Rodney
Latz, Jane E.
Wakelee, Heather A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
[24] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
Robert, Francisco
Sandler, Alan
Schiller, Joan H.
Liu, Glenn
Harper, Karen
Verkh, Lev
Huang, Xin
Ilagan, Jennifer
Tye, Lesley
Chao, Richard
Traynor, Anne M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
[25] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
Francisco Robert
Alan Sandler
Joan H. Schiller
Glenn Liu
Karen Harper
Lev Verkh
Xin Huang
Jennifer Ilagan
Lesley Tye
Richard Chao
Anne M. Traynor
Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
[26] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
Gordon, Michael S.
Springett, Gregory M.
Su, Yungpo Bernard
Ould-Kaci, Mahmoud
Wind, Sven
Zhao, Yihua
LoRusso, Patricia M.
FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
[27] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Sukhmani K. Padda
Yelena Krupitskaya
Laveena Chhatwani
George A. Fisher
Alexander D. Colevas
Melanie San Pedro-Salcedo
Rodney Decker
Jane E. Latz
Heather A. Wakelee
Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
[28] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
Wu, Yi-Long
Cheng, Ying
Chen, Huajun
Tu, Haiyan
Xu, Chongrui
Wang, Zhen
Liu, Ying
Xin, Ying
Lou, Haizhou
Wang, Wei
Chin, Kevin
Li, Dandan
Zhao, Di
Gao, Yanfei
Xu, Wenping
Pan, Hongming
FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
[29] Phase I study of BI 836880 alone or combined with ezabenlimab in Japanese patients (pts) with advanced solid tumors
Yamazaki, Kentaro
Koyama, Takafumi
Shimizu, Toshio
Todaka, Akiko
Kawakami, Takeshi
Yoon, Jangsoo
Erzen, Damijan
Hou, Jianrui
Yamamoto, Noboru
ANNALS OF ONCOLOGY, 2022, 33 : S506 - S506
[30] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations.
Heymach, John
Opdam, Frans
Barve, Minal A.
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yamamoto, Noboru
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →